With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

In the growth disorders business, Novo Nordisk is also launching a new weekly growth hormone treatment. The global healthcare company, founded in 1923, has addressed unmet medical needs of people ...

Novo Nordisk has started building ... up 3% on the same period of 2023 - but Novo Nordisk has a stated ambition of generating a "sustained growth outlook" for the business as sales of some ...

Novo Nordisk A/S ... rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.